$8 Billion Award Granted in Risperdal Lawsuit
Plaintiff's attorneys say drug is linked to abnormal growth of female breast tissue in boys
WEDNESDAY, Oct. 9, 2019 (HealthDay News) -- A lawsuit over the antipsychotic drug Risperdal has led to an $8 billion punitive damages award against Johnson & Johnson and one if its subsidiaries.
The award was handed out Tuesday by a Philadelphia jury. The plaintiff's attorneys argued that the drug is linked to abnormal growth of female breast tissue in boys, the Associated Press reported.
In a statement, attorneys Tom Kline and Jason Itkin said Johnson & Johnson used an organized scheme to make billions of dollars while illegally marketing and promoting the drug.
Johnson & Johnson said the award is "excessive and unfounded" and that it would take immediate action to overturn it, the AP reported.